JESMONEET BOBB-DIALLO: Open Payments
NPI 1669917605 · LIVERPOOL, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,523 in 49 payments from 9 companies in 2025. Trend: 2023 $22 · 2024 $74 · 2025 $1,523
Food & beverage: $1,523
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 12 | $410 |
| Alkermes, Inc. | 11 | $368 |
| Braeburn Inc. | 7 | $217 |
| Otsuka America Pharmaceutical, Inc. | 7 | $146 |
| Luye Pharma (USA) Ltd. | 3 | $144 |
| Gilead Sciences, Inc. | 1 | $112 |
| Teva Pharmaceuticals USA, Inc. | 6 | $94 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Orexo US, Inc. | 1 | $15 |
Products named: COBENFY, BRIXADI, ARISTADA, ERZOFRI EXTENDED-RELEASE, ABILIFY ASIMTUFII, LYBALVI, Epclusa, UZEDY.
Industry payments across NY — which companies pay providers there.
